Reply: active and native vitamin D in critical illness.
暂无分享,去创建一个
D. Leaf | A. Ginde | M. Donnino | S. Waikar | A. Raed
[1] A. Berghold,et al. Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial. , 2014, JAMA.
[2] D. Leaf,et al. Randomized controlled trial of calcitriol in severe sepsis. , 2014, American journal of respiratory and critical care medicine.
[3] Katrice A Lippa,et al. An assessment of 25-hydroxyvitamin D measurements in comparability studies conducted by the Vitamin D Metabolites Quality Assurance Program. , 2013, Clinica chimica acta; international journal of clinical chemistry.
[4] M. Blans,et al. Incidence and aetiology of renal phosphate loss in patients with hypophosphatemia in the intensive care unit , 2013, Intensive Care Medicine.
[5] J. Bacchetta,et al. Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25‐dihydroxyvitamin D in human monocytes , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] Herbert Chase,et al. FGF-23 levels in patients with AKI and risk of adverse outcomes. , 2012, Clinical journal of the American Society of Nephrology : CJASN.
[7] Y. Ahmed,et al. Worsening severity of vitamin D deficiency is associated with increased length of stay, surgical intensive care unit cost, and mortality rate in surgical intensive care unit patients. , 2012, American journal of surgery.
[8] A. Ponsonby,et al. Variability in vitamin D assays impairs clinical assessment of vitamin D status , 2012, Internal medicine journal.
[9] Chi-yuan Hsu,et al. FGF-23 and PTH levels in patients with acute kidney injury: A cross-sectional case series study , 2011, Annals of intensive care.
[10] T. Pieber,et al. Short-term effects of high-dose oral vitamin D3 in critically ill vitamin D deficient patients: a randomized, double-blind, placebo-controlled pilot study , 2011, Critical care.
[11] T. Shimada,et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. , 2010, Kidney international.
[12] L. Nagy,et al. 1,25-Dihydroxyvitamin D3 Is an Autonomous Regulator of the Transcriptional Changes Leading to a Tolerogenic Dendritic Cell Phenotype12 , 2009, The Journal of Immunology.
[13] J. Zerwekh. Blood biomarkers of vitamin D status. , 2008, The American journal of clinical nutrition.
[14] A. Hutson,et al. A Phase I Pharmacokinetic and Pharmacodynamic Study of Intravenous Calcitriol in Combination with Oral Gefitinib in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.
[15] S. Kato,et al. Role of the vitamin D receptor in FGF23 action on phosphate metabolism. , 2005, The Biochemical journal.
[16] D. Steinhilber,et al. 22‐ene‐25‐oxa‐vitamin D: a new vitamin D analogue with profound immunosuppressive capacities , 2005, European journal of clinical investigation.
[17] R. Kumar,et al. Gene expression profiles in dendritic cells conditioned by 1α,25-dihydroxyvitamin D3 analog , 2004, The Journal of Steroid Biochemistry and Molecular Biology.